Bionxt Solutions’ experimental sublingual therapy BNT23001 led to about 40% higher blood exposure to cladribine than a conventional oral tablet formulation, such as those used in multiple sclerosis (MS) therapies like Mavenclad, the company reported. The results come from a preclinical study in adult miniature pigs,…
News
When immune B-cells mistakenly recognize the body’s own nerve tissue, they can shut themselves down to prevent damage, but infection with the Epstein-Barr virus (EBV) can trick B-cells into surviving and becoming activated in the brain instead of being eliminated by normal immune safety mechanisms, according to a study.
Hyperfine’s Swoop system, the first U.S. Food and Drug Administration (FDA)-cleared AI-powered portable MRI system for the brain, showed strong diagnostic agreement with conventional MRI scans and was preferred by patients, according to new study results. Because Swoop can be used in neurology clinics, it may help make…
People whose biological mothers had diabetes during pregnancy are more likely to develop multiple sclerosis (MS) as adults, according to a new study from Norway. The study also found that MS risk is heightened among people who were born unusually large, while babies who were abnormally small at birth…
Brenig Therapeutics has launched an early Phase 1 clinical trial to evaluate its experimental small molecule BT-409Â in healthy volunteers. The therapy is being developed for people with multiple sclerosis (MS) and other chronic neurologic conditions. It is aimed at blocking inflammatory responses by targeting the NLRP3 inflammasome,…
Taking oral caffeine supplements may significantly reduce fatigue and improve quality of life and mood in people with multiple sclerosis (MS), according to a recent clinical trial in Iran. Participants took 100 mg of caffeine tablets daily for 12 weeks, equivalent to about two shots of espresso, or a…
A brain protein called anoctamin-2 (ANO2) has emerged as a new piece of the puzzle linking Epstein-Barr virus (EBV) infections to multiple sclerosis (MS), according to a study. Researchers found that immune T-cells from people with MS can mistake ANO2 for an EBV protein, triggering a cross-reactive response…
A new machine learning tool can now help predict whether people newly diagnosed with multiple sclerosis (MS) will experience disability worsening that occurs even in the absence of relapses. According to a recent study, these artificial intelligence algorithms can identify the risk of “progression independent of relapse activity,” or…
Paralyzed Veterans of America (PVA) — a congressionally chartered veterans organization open to all military service members with multiple sclerosis (MS) — has launched a new, free, online fitness and wellness program that offers adaptive, expert-led classes for individuals with mobility challenges. The initiative is designed specifically…
A history of the Epstein-Barr virus (EBV) appears to alter the immune systems of people with specific genetic traits, causing their own cells to mistakenly flag brain proteins as dangerous threats, according to a new study. This discovery offers insight into how these risk factors — viral infection and…
A greater intake of vitamin D, from both food and supplements, was linked to a 42% lower risk of developing multiple sclerosis (MS) among women living in Norway, according to a large prospective study. “Our findings suggest that a higher dietary intake of vitamin D decreases the risk of…
Find Therapeutics has secured CA$10 million (approximately $7.4 million) in funding to continue advancing tasronetide, its lead candidate for boosting myelin repair in people with multiple sclerosis (MS). The Series A extension financing round follows the completion of a Phase 1 trial in healthy volunteers, in which tasronetide…
People with multiple sclerosis (MS) who have mild disability still experience several disease-related difficulties at work — challenges that can lead employees to shift to part-time or possibly quit their jobs — even after their condition is disclosed, a new study in Norway highlights. In particular, there are three…
A group of international experts has proposed a first-of-its-kind framework aimed at preventing multiple sclerosis (MS) from developing. Rather than focusing on a single cause, the framework outlines multiple opportunities to lower MS risk across a person’s life, from reducing childhood obesity and viral exposures to addressing smoking and…
Evogene and Unravel Biosciences are collaborating to develop a new class of therapies targeting myelin repair in multiple sclerosis (MS) and similar disorders. By combining two distinct artificial intelligence platforms, the companies hope to create the first treatment capable of…
Inflammatory gut bacteria that carry proteins structurally similar to myelin, a protective layer surrounding nerve fibers that is damaged in multiple sclerosis (MS), may trigger the development and progression of the disease, according to a new study done in mouse models. The findings may pave the way toward new…
Multiple sclerosis (MS) may follow two distinct biological paths that differ in how early and how quickly nerve damage develops, according to a new study. Using artificial intelligence (AI) to analyze brain MRI scans together with a blood test linked to nerve damage, researchers identified one MS pattern marked…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to privosegtor, an experimental treatment from Oculis that aims to protect the vision of people experiencing acute optic neuritis. This condition, which involves inflammation of the optic nerve, is a common and often debilitating symptom of…
The balance between two immune signaling molecules — CXCL13 and BAFF — may help identify the hard-to-treat inflammation in the brain and spinal cord that’s thought to be a major driver of disability progression in multiple sclerosis (MS), a study found. The findings may help identify which patients are…
The U.S. Food and Drug Administration (FDA) has approved Scinopharm Taiwan’s glatiramer acetate injection, a generic of Copaxone, to treat multiple sclerosis (MS). Scinopharm is the first pharmaceutical company in Taiwan to win U.S. approval for glatiramer acetate, marking a significant milestone…
The National Institute for Health and Care Excellence (NICE) in England is recommending natalizumab — sold as Tysabri and Tyruko — as an option for certain people with hard-to-control multiple sclerosis (MS). NICE is responsible for deciding which medicines will be covered by the National Health Service…
Women with multiple sclerosis (MS) who have children experience significantly longer waits before receiving a diagnosis than women without children, according to a new U.S. study. On average, each child was associated with an additional 1.28-year delay in diagnosis. The delay was even longer among women whose symptoms…
Tiziana Life Sciences‘ intranasal spray foralumab continues to be safe and well-tolerated, with no drug-related serious side effects reported after long-term use, according to an annual report filed with the U.S. Food and Drug Administration (FDA). The company is developing foralumab for neuroinflammatory diseases such as multiple…
Quantum Biopharma has completed dosing in two toxicology studies requested by the U.S. Food and Drug Administration (FDA) that aim to support the launch of clinical studies of Lucid-MS, an experimental treatment for multiple sclerosis (MS) that’s designed to slow myelin loss. The 180-day toxicity and toxicokinetic…
Throughout 2025, the team at Multiple Sclerosis News Today brought our readers the latest advances and updates in research related to multiple sclerosis (MS). Below are the top 10 most-read news stories we published this year. We look forward to continuing to serve the MS community in 2026 and…
After months of delay, the U.S. Food and Drug Administration (FDA) has rejected Sanofi‘s application seeking approval of tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (MS). While Sanofi announced earlier this month that the decision was likely to be delayed again…
Disability progression in relapsing forms of multiple sclerosis (MS) tends to follow one of four distinct patterns, according to long-term data from more than 5,000 people with relapsing-onset MS followed in an Italian registry. The study specifically found that disability progression could generally be categorized into four patterns: minimal-worsening,…
Immutep’s experimental immunotherapy, IMP761, continues to demonstrate a favorable safety profile, along with sustained suppression of T-cell activity, immune cells that are overly active in multiple sclerosis (MS) and other autoimmune diseases. These findings are based on data from healthy people enrolled in an ongoing first-in-human Phase 1…
People exposed to higher levels of certain manufactured compounds that persist in the environment are more likely to be diagnosed with multiple sclerosis (MS), a new study reports. A higher MS risk was associated with elevated levels of PFAS, also known as “forever chemicals,” and specific metabolites of PCBs,…
Fear of a sudden relapse or a gradual worsening of MS symptoms is common among people with multiple sclerosis (MS), according to a systematic review analyzing data from more than 3,000 people with MS. Those fears are not only widespread but also closely tied to poorer mental health, greater fatigue,…